Seek Returns

DHR vs. VTRS: Danaher vs. Viatris Stock Comparison

How do Danaher (DHR) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Danaher (DHR) and Viatris (VTRS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but DHR is classified in Life Sciences Tools & Services while VTRS is classified in Pharmaceuticals.

Company profile comparison for Danaher (DHR) and Viatris (VTRS)
Profile ItemDHRVTRS
NameDanaher Corp.Viatris Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesPharmaceuticals
GICS Sub-IndustryLife Sciences Tools & ServicesPharmaceuticals
Market Capitalization161.86 billion USD22.83 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateDecember 29, 1978March 17, 1980
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

DHR
VTRS
GSPC
Loading price history…
Danaher (DHR) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Danaher (DHR) and Viatris (VTRS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Danaher (DHR) and Viatris (VTRS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Danaher (DHR) and Viatris (VTRS)
MetricDHRVTRS
Total Return (1Y)11.88%108.98%
Total Return (3Y, Annualized)6.67%36.75%
Total Return (5Y, Annualized)-2.05%11.59%

Risk Profile

Drawdown History

DHR
VTRS
GSPC
Loading price history…
Danaher (DHR) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Danaher (DHR) and Viatris (VTRS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Danaher (DHR) and Viatris (VTRS)
MetricDHRVTRS
Volatility (1Y, Annualized)30.61%32.53%
Beta (5Y)0.760.86
Max Drawdown (5Y)-43.31%-45.69%
Avg. Volume (3M)3.94M8.87M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
DHR and VTRS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Danaher (DHR) and Viatris (VTRS)
MetricDHRVTRS
Sharpe Ratio (1Y)0.253.22
Sortino Ratio (1Y)0.355.63

Profitability

ROE (TTM)

Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Danaher (DHR) reports 8.19%, ranking against industry peers normally.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.19%

Max
109.18%
DHR
8.19%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.21%

Max
109.18%
Q3
6.23%
VTRS
-4.21%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Danaher (DHR) vs. Viatris (VTRS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Danaher (DHR) reports 16.91%, ranking against industry peers normally.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.91%

Max
18.05%
DHR
16.91%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.13%

Max
18.05%
Q3
4.78%
Median
0.00%
VTRS
-4.13%
Q1
-4.14%
Min
-17.05%
Loading chart…
Danaher (DHR) vs. Viatris (VTRS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Danaher (DHR) at 21.13% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.13%

Max
83.12%
DHR
21.13%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.85%

Max
83.12%
Q3
14.77%
VTRS
13.85%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Danaher (DHR) vs. Viatris (VTRS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Danaher (DHR) and Viatris (VTRS)
MetricDHRVTRS
ROE (TTM)8.19%-4.21%
ROA (TTM)4.06%2.91%
Net Margin (TTM)16.91%-4.13%
Operating Margin (TTM)21.13%13.85%
Gross Margin (TTM)59.36%41.13%

Growth

Revenue Growth

Danaher (DHR) at 2.90% is around its peer norm for revenue growth, while Viatris (VTRS) at -2.98% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Loading chart…
Danaher (DHR) vs. Viatris (VTRS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Danaher (DHR) reports EPS growth of -4.54%, ranked against its industry; Viatris (VTRS) has no EPS growth figure this period.

Loading chart…
Danaher (DHR) vs. Viatris (VTRS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Danaher (DHR) and Viatris (VTRS)
MetricDHRVTRS
Revenue Growth (YoY)2.90%-2.98%
Revenue Growth (3Y CAGR)-2.67%-4.20%
EPS Growth (YoY)-4.54%--
EPS Growth (3Y CAGR)-19.44%--

Financial Strength

Current Ratio (MRQ)

Both Danaher (DHR) at 1.63 and Viatris (VTRS) at 1.55 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.63

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
DHR
1.63
Min
0.10

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
VTRS
1.55
Min
0.10
Loading chart…
Danaher (DHR) vs. Viatris (VTRS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Danaher (DHR) at 0.52 carries an industry-typical debt-to-equity mix, while Viatris (VTRS) at 0.99 uses more debt funding than most peers.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.52

Max
1.42
Q3
0.65
DHR
0.52
Median
0.15
Q1
0.02
Min
0.00

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.99

Max
1.42
VTRS
0.99
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Danaher (DHR) vs. Viatris (VTRS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Danaher (DHR) and Viatris (VTRS)
MetricDHRVTRS
Current Ratio (MRQ)1.631.55
Debt / Equity (MRQ)0.520.99
Net Debt / EBITDA2.682.64

Dividends

Dividend Yield (TTM)

Both Danaher (DHR) at 0.67% and Viatris (VTRS) at 2.53% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.67%

DHR
0.67%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.53%

VTRS
2.53%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Danaher (DHR) vs. Viatris (VTRS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Danaher (DHR) reports 25.17%, ranking against industry peers normally.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.17%

DHR
25.17%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

960.00%

VTRS
960.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Danaher (DHR) vs. Viatris (VTRS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Danaher (DHR) and Viatris (VTRS)
MetricDHRVTRS
Dividend Yield (TTM)0.67%2.53%
Dividend Payout Ratio (TTM)25.17%960.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Danaher (DHR) trades at 38.12 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.12

Max
85.34
Q3
43.46
DHR
38.12
Median
26.69
Q1
13.30
Min
0.07

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
VTRS
--
Loading chart…
Danaher (DHR) vs. Viatris (VTRS): VTRS does not report P/E ratio, so it has no value marker; DHR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Viatris (VTRS) at 1.55 sits in the cheaper P/S ratio quartile while Danaher (DHR) at 6.32 prices around its industry’s middle — VTRS costs less per dollar of sales, though read it alongside growth and margins.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.32

Max
58.18
Q3
25.77
Median
7.30
DHR
6.32
Q1
3.01
Min
0.01

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
VTRS
1.55
Min
0.01
Loading chart…
Danaher (DHR) vs. Viatris (VTRS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Viatris (VTRS) at 1.67 sits in the lower P/B ratio quartile against book while Danaher (DHR) at 3.02 is valued near its industry’s middle — VTRS is cheaper on assets, though weigh it against ROE and asset quality.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.02

Max
13.53
Q3
6.54
Median
3.25
DHR
3.02
Q1
1.69
Min
-5.59

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.67

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
VTRS
1.67
Min
-5.59
Loading chart…
Danaher (DHR) vs. Viatris (VTRS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Danaher (DHR) and Viatris (VTRS)
MetricDHRVTRS
P/E Ratio (TTM)38.12--
P/S Ratio (TTM)6.321.55
P/B Ratio (MRQ)3.021.67
Free Cash Flow Yield (TTM)2.93%13.84%